Aurora Cannabis (ACB) FWP Free writing prospectus

ISSUER FREE WRITING PROSPECTUS

Filed pursuant to Rule 433

Registration Statement No.: 333-249680

Dated November 11, 2020

AURORA CANNABIS INC. OFFERING OF UNITS November 11, 2020

A final base shelf prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the provinces of Canada (except Québec). A copy of the final base shelf prospectus, any amendment to the final base shelf prospectus and any applicable shelf prospectus supplement that has been filed, is required to be delivered with this document.

This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the final base shelf prospectus, any amendment and any applicable shelf prospectus supplement for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

ISSUER:	Aurora Cannabis Inc. (“Aurora” or the “Company”)
AMOUNT:	US$150,000,000
ISSUE:	Treasury offering of 20,000,000 units of the Company (“Units”).
ISSUE PRICE:	US$7.50 per Unit
UNITS:	Each Unit consists of one common share of the Issuer (a “Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”).
COMMON SHARE PURCHASE WARRANTS:	Each whole Warrant will entitle the holder to acquire one Share from the Company at a price of US$9.00 per Share for a period of 40 months following Closing.
OVER-ALLOTMENT OPTION:	The Company has granted the underwriters an option, exercisable at the Issue Price at any time up to 30 days following the closing of the offering, to purchase up to an additional 15% of the offering (which may be comprised of the acquisition of additional Units, Shares and/or Warrants) to cover overallotments, if any.
USE OF PROCEEDS:	The Company plans to use the net proceeds of the offering to fund growth opportunities, working capital, and other general corporate purposes.
LISTING:	Application will be made to list the Common Shares on the Toronto Stock Exchange (the “TSX”) and on the New York Stock Exchange (the “NYSE”) and the Warrants on the TSX. Listing will be subject to fulfilling all the listing requirements of the TSX and NYSE, respectively, including distribution of the Warrants to a minimum number of public securityholders. The existing common shares of the Company are listed on the TSX under the symbol “ACB” and the NYSE under the symbol “ACB”.
FORM OF OFFERING:	Public offering by way of a final base shelf prospectus and prospectus supplement filed in each of the provinces of Canada (except Québec) and pursuant to the multijurisdictional disclosure system in the United States.
ELIGIBILITY:	Eligible for DPSPs, RDSPs, RESPs, RRIFs, RRSPs and TFSAs.
BOOKRUNNERS:	BMO Capital Markets and ATB Capital Markets Inc.
CO-MANAGERS:	CIBC Capital Markets
UNDERWRITING FEE:	4.75%
PRICING DATE:	November 11, 2020
CLOSING DATE:	November 16, 2020

2

The Company has filed a registration statement (including a prospectus) with the United States Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you may request it from BMO Capital Markets, Brampton Distribution Centre C/O The Data Group of Companies, 9195 Torbram Road, Brampton, Ontario, L6S 6H2 (905-791-3151 Ext 431; torbramwarehouse@datagroup.ca) or from BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036 (800-414-3627; bmoprospectus@bmo.com); or from ATB Capital Markets Inc., Attn: Gail O’Connor, 410-585 8th Ave SW, Calgary, Alberta, T2P 1G1 (+1 (403) 539-8629; atbcm_dealflow@atb.com).

Investing in securities of the Company involves a high degree of risk. You should carefully review the risks outlined in the final base shelf prospectus (together with any prospectus supplement) and in the documents incorporated by reference in the final base shelf prospectus and any prospectus supplement and consider such risks in connection with an investment in such securities. See “Risk Factors” in the final base shelf prospectus.

Prospective investors should be aware that the acquisition of the securities described herein may have tax consequences both in the United States and in Canada. Such consequences for investors who are resident in, or citizens of, the United States may not be described fully in the final base shelf prospectus. Prospective investors should read the tax discussion contained in the applicable prospectus supplement with respect to the offering described herein.